Apollomics, Inc. Presents Positive Preclinical Data on APL-102, an oral Multi-Kinase Inhibitor with CSF-1R Activity

NEXT STORY
BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting
PREV STORY
American College of Rheumatology Targets Step Therapy and Drug Pricing in New Position Statements
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Pieris Pharmaceuticals to Present at 43rd Annual Deutsche Bank Health Care Conference

BOSTON, May 03, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel ...

author_avatar
NASDAQ Market News

Freeline announces supply agreement for haemophilia B program

author_avatar
NASDAQ Market News

Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General Manager, Europe

author_avatar
NASDAQ Market News